Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 19.8% in February

Allogene Therapeutics, Inc. (NASDAQ:ALLO) saw a large growth in short interest in February. As of February 27th, there was short interest totaling 23,927,216 shares, a growth of 19.8% from the February 12th total of 19,964,416 shares. Based on an average daily trading volume, of 6,048,498 shares, the days-to-cover ratio is currently 4.0 days. Approximately 12.3% of the company’s shares are sold short. Approximately 12.3% of the company’s shares are sold short. Based on an average daily trading volume, of 6,048,498 shares, the days-to-cover ratio is currently 4.0 days.

Key Allogene Therapeutics News

Here are the key news stories impacting Allogene Therapeutics this week:

• Positive Sentiment: Canaccord Genuity reaffirmed a “buy” rating and set a $14.00 price target (huge upside vs. current levels), which could attract bargain-hunting and institutional interest. Benzinga
• Positive Sentiment: Piper Sandler raised its price target from $7.00 to $8.00 and maintained an “overweight” rating, signaling improved sell-side confidence in ALLO’s commercial/clinical outlook. Benzinga TickerReport
• Positive Sentiment: Q4 results: ALLO reported a narrower-than-expected loss (EPS -$0.17 vs. consensus -$0.25), highlighted expense reductions, and said cash should fund operations into 2028 — all supportive of near-term financial stability and de-risking. Zacks
• Neutral Sentiment: The company filed its full Q4/FY2025 press release and provided a business update detailing pipeline progress and finances; investors can review details for clinical timelines and cash burn assumptions. GlobeNewswire
• Neutral Sentiment: Earnings call transcript published — useful for details on trial milestones, timelines, and management commentary but not new headline news by itself. Seeking Alpha
• Neutral Sentiment: Short-interest notices in the feed report a “significant increase” but show inconsistent/zero values (likely data/reporting noise); monitor filings for any confirmed rise in short interest. (No reliable link available in the report.)

Allogene Therapeutics Stock Down 2.8%

Shares of NASDAQ:ALLO opened at $2.40 on Monday. The firm has a 50 day moving average of $1.94 and a 200 day moving average of $1.51. The company has a market capitalization of $585.07 million, a price-to-earnings ratio of -2.76 and a beta of 0.50. Allogene Therapeutics has a 52 week low of $0.86 and a 52 week high of $2.80.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.08. On average, sell-side analysts expect that Allogene Therapeutics will post -1.28 EPS for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on ALLO shares. Citigroup raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Friday, January 9th. Piper Sandler upped their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock an “overweight” rating in a report on Friday. Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price target on shares of Allogene Therapeutics in a research report on Friday. Citizens Jmp upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research note on Friday, January 9th. Finally, Wall Street Zen upgraded Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.50.

Insider Activity at Allogene Therapeutics

In other Allogene Therapeutics news, EVP Zachary Roberts sold 35,700 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $1.77, for a total value of $63,189.00. Following the completion of the sale, the executive vice president directly owned 581,166 shares of the company’s stock, valued at $1,028,663.82. The trade was a 5.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Geoffrey M. Parker sold 24,001 shares of the company’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.76, for a total transaction of $42,241.76. Following the completion of the transaction, the chief financial officer owned 1,252,795 shares in the company, valued at $2,204,919.20. This represents a 1.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 222,987 shares of company stock worth $396,969. Corporate insiders own 13.20% of the company’s stock.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Savant Capital LLC purchased a new position in Allogene Therapeutics in the third quarter valued at about $27,000. Russell Investments Group Ltd. lifted its position in shares of Allogene Therapeutics by 11,159.8% during the third quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company’s stock valued at $27,000 after buying an additional 21,650 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company’s stock valued at $30,000 after buying an additional 23,599 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at about $30,000. Finally, Brighton Jones LLC boosted its holdings in shares of Allogene Therapeutics by 81.6% in the 3rd quarter. Brighton Jones LLC now owns 25,168 shares of the company’s stock valued at $31,000 after buying an additional 11,311 shares in the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Company Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.